Special Issue

Targeting Mitochondria in Anti-tumor Drug Development

Message from the Guest Editors

Metabolic reprogramming in cancer is a well-known phenomenon and experimental evidence demonstrates that invasive migratory cancer cells often switch to elevated mitochondrial metabolism, which is not the primary target of current oncotherapies, often resulting in a poor outcome or relapse. Thus, the development of novel anti-cancer drugs or repurposing of known medicines targeting tumor metabolism can be promising anticancer strategies. The purpose of this Special Issue is to discuss the latest research into drug development targeting tumor metabolism, particularly focusing on metabolic vulnerabilities in mitochondria. Original research articles as well as reviews are welcome.

Guest Editors

Dr. Bela Ozsvari

Dr. Nadia J. Jacobo-Herrera

Dr. Carlos Pérez-Plasencia

Deadline for manuscript submissions

closed (15 June 2024)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/187212

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)